Skip to main content

Hypogammaglobulinemia

1
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Prothya Biosolutions
Prothya BiosolutionsBelgium - Brussels
1 program
1
IVIG-LPhase 2/31 trial
Active Trials
NCT00138697Completed15Est. Dec 2004
Grifols
GrifolsNEW YORK, NY
3 programs
IVIGN/A1 trial
IVIGPHASE_21 trial
XembifyPHASE_31 trial
Active Trials
NCT02043379Completed50Est. Jun 2015
NCT00115778Completed11Est. Aug 2010
NCT05645107Recruiting386Est. Jun 2026
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
subcutaneous immunoglobulinN/A
CSL Behring
CSL BehringIL - Bradley
1 program
subcutaneous immunoglobulinN/A1 trial
Active Trials
NCT03401268Completed20Est. May 2019
Octapharma
OctapharmaAustria - Vienna
1 program
Panzyga, 10% Intravenous SolutionPHASE_31 trial
Active Trials
NCT07220915Not Yet Recruiting360Est. Dec 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
OctapharmaPanzyga, 10% Intravenous Solution
GrifolsXembify
Prothya BiosolutionsIVIG-L
GrifolsIVIG
CSL Behringsubcutaneous immunoglobulin
GrifolsIVIG

Clinical Trials (6)

Total enrollment: 842 patients across 6 trials

NCT07220915OctapharmaPanzyga, 10% Intravenous Solution

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Start: Dec 2025Est. completion: Dec 2029360 patients
Phase 3Not Yet Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Start: Dec 2022Est. completion: Jun 2026386 patients
Phase 3Recruiting

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

Start: May 2001Est. completion: Dec 200415 patients
Phase 2/3Completed

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Start: Jun 2005Est. completion: Aug 201011 patients
Phase 2Completed
NCT03401268CSL Behringsubcutaneous immunoglobulin

Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients

Start: Feb 2018Est. completion: May 201920 patients
N/ACompleted

Post-bypass Prophylactic IVIG in Infants and Neonates

Start: May 2014Est. completion: Jun 201550 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 842 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.